We are a late stage biopharmaceutical business commercialising a promising new vaccine for a range of common respiratory diseases.
Our goal is to build significant long term shareholder value by helping dramatically improve the quality of life for patients with these chroniccondtions.
Hunter Immunology plans to list on the Australian Securities Exchange in April 2012 through a takeover of the listed company Probiomics.
Hunter Immunology is committed to clear and transparent communication with all its stakeholders. This document is a list of answers to common investor questions.
We are entering an exciting new phase of our global commercial development. If you would like to receive email updates on our progress and public announcements, please submit your email address here*
*Please note we will only use your email address to send you more information about Hunter Immunology. Your email address will not be shared with any third parties
Our lead product is a vaccine currently called HI-164OV. It works by controlling bacterial colonisation of airways damaged by inhaled toxins.
It has been developed to treat patients with Chronic Obstructive Pulmonary Disease (COPD) which includes bronchitis and emphysema.
HI-164OV could help improve the lives of over one million Australians with COPD, and contribute towards saving Australia more than $300m in healthcare costs.
The global incidence of airways diseases like COPD is growing rapidly in direct proportion to the rise in airborne pollutants and smoking in the developing world.
The results of a major Phase IIb clinical study of the vaccine carried out at 21 Australian hospitals are due to be released mid year 2012.
An earlier Phase IIa study produced positive results and the data was published in 2010 (pdf).
Dr. Phillip Comans
Chief Executive Officer
Hunter Immunology Limited
Suite 1005, 4 Bridge Street, Sydney NSW 2000
Tel: +61 (0) 439-466-116
Thank you for subscribing to Hunter Immunology